There are trials during and after a drug's lifecycle. Before it is put on the market, during the clinical trials, there is a safety program. There is—
real world evidence that we collect,
Those are the requirements of regulatory bodies like Health Canada or the FDA. After the end of a drug's lifecycle, we have to keep providing information that it is not harmful for 25, 30 and even 50 years. We exchange all the details with Health Canada and other public bodies. It is important to mention that a drug's profile can change over time because of its use in clinical situations.
Mr. Lexchin did not criticize our industry, but he did mention a very important point. Let me give you one example. A product is approved by Health Canada and goes onto the market. It is well used clinically and works very well for the patients. However, as Mr. Young well knows, after five or six years, a new drug or natural product may appear on the market and is contraindicated because of its interactions with the drug already on the market. There can be adverse effects because of that contraindication. We have to keep providing all those details.
As we mentioned in our remarks, the dialogue with Health Canada and the manufacturers must be enhanced when a case of adverse effects is reported by a hospital or another clinical institution.